We conducted a retrospective cohort study to quantify, by breast cancer stage (early, locally advanced, metastatic), the proportion of cases identified in electronic medical records (EMRs) as ‘HER2-negative’ who had low or ultralow levels of HER2 expression. Here, ERBB2 is linked to breast carcinoma.